Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 09, 2026 | June 11, 2026 |
| Electra Therapeutics, Inc.ETRA · Entity 9265 | Director | September 18, 2026 | September 18, 2026 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 16, 2019 | May 20, 2019 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director | May 27, 2026 | May 29, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,188 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 12,000 · Balance 30,188 F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Electra Therapeutics, Inc.
Report date September 18, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2033-11-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 · Expires 2036-02-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-09-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.
MACROGENICS INC
Report date May 16, 2019 · Filed May 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2029-05-16 | Direct | 10,000 |
Reported balance
After 2019-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,696 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 33,696 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 22,836 · Balance 5,925 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 5,925 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2028-03-16 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 2,092 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.32 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.71 · Expires 2034-06-07 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-01 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.33 · Expires 2035-06-11 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Disposition to issuer · Disposed 10,350 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2036-06-18 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Disposition to issuer · Disposed 9,730 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Dermira, Inc.
Report date February 20, 2020 · Filed February 25, 2020
Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 5,051 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 14,224 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,730 | $49.13 Strike: $35.87 | $478,034.90 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · derivative · entry 7 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,730 shares Expires 2036-06-18 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,350 | $52.67 Strike: $32.33 | $545,134.50 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · derivative · entry 6 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,350 shares Expires 2035-06-11 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | $40.29 Strike: $44.71 | $503,625.00 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · derivative · entry 5 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2034-06-07 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,500 | $64.68 Strike: $20.32 | $1,131,900.00 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · derivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2033-06-15 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,092 | $83.09 Strike: $1.91 | $173,824.28 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,092 shares Expires 2028-03-16 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 5,925 | $85.00 | $503,625.00 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 22,836 | $85.00 | $1,941,060.00 |
DisclosureSEC source: 0001628280-26-059902 · wk-form4_1788296467.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,925 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (Right to Buy) · Derivative | 9,730 | $0.00 Strike: $35.87 | $0.00 |
DisclosureSEC source: 0001628280-26-044717 · wk-form4_1782162344.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,730 Underlying: Common Stock · 9,730 shares Expires 2036-06-18 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 5,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-044717 · wk-form4_1782162344.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,761 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002920 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,188 F1 · shares: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001610717-26-000173 · form4.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-05-26 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 14,058 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001397266-26-000002 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,058 Underlying: Common Stock · 14,058 shares Expires 2036-05-14 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001397266-26-000002 · ownership.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,696 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:41 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001658247-25-000010 · wk-form4_1759264890.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,092 Underlying: Common Stock · 10,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/3rd of the options vested on February 16, 2019, and 1/36th of the options vested monthly thereafter. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:41 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 16,000 | $44.75 | $716,000.00 |
DisclosureSEC source: 0001658247-25-000010 · wk-form4_1759264890.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,836 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2024. F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $44.75 per share. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:41 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 10,000 | $1.91 | $19,100.00 |
DisclosureSEC source: 0001658247-25-000010 · wk-form4_1759264890.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 10,350 | $0.00 Strike: $32.33 | $0.00 |
DisclosureSEC source: 0000950170-25-086266 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,350 Underlying: Common Stock · 10,350 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086266 · ownership.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,836 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002141 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,188 F1 · shares: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 7 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-05-27 F5 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 6 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 27,802 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 5 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,802 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 85,586 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,586 Underlying: Common Stock · 85,586 shares Expires 2031-04-23 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,802 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 85,586 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079925 · ownership.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,586 shares Expires 2031-04-23 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0000950170-25-074664 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 10,787 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074664 · ownership.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,945 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022326 · ownership.xml · derivative · entry 6 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 27,802 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022326 · ownership.xml · derivative · entry 5 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,802 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 85,586 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022326 · ownership.xml · derivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,586 Underlying: Common Stock · 85,586 shares Expires 2031-04-23 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $9.95 | Not disclosed |
DisclosureSEC source: 0000950170-25-022326 · ownership.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,802 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-022326 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 85,586 | Not disclosed Strike: $2.51 | Not disclosed |
DisclosureSEC source: 0000950170-25-022326 · ownership.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,586 shares Expires 2031-04-23 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,844 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · derivative · entry 12 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,586 Underlying: Common Stock · 7,844 shares Expires 2031-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,205 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · derivative · entry 11 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,205 shares Expires 2030-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 14,049 | $17.03 | $239,319.10 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 7 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,100 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionCommon Stock | 7,844 | $2.52 | $19,766.88 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 6 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionCommon Stock | 6,205 | $8.79 | $54,541.95 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 5 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,156 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · derivative · entry 10 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,430 Underlying: Common Stock · 2,156 shares Expires 2031-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · derivative · entry 9 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,205 Underlying: Common Stock · 1,800 shares Expires 2030-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,783 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · derivative · entry 8 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,783 shares Expires 2030-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 7,739 | $17.01 | $131,642.71 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,100 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionCommon Stock | 2,156 | $2.52 | $5,433.12 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionCommon Stock | 1,800 | $8.79 | $15,822.00 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Exercise / conversionCommon Stock | 3,783 | $8.32 | $31,474.56 |
DisclosureSEC source: 0001610717-24-000511 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,900 | $0.00 Strike: $37.42 | $0.00 |
DisclosureSEC source: 0000950170-24-075489 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075489 · ownership.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,205 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:13 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001610717-24-000335 · form4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:13 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000335 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.